Literature DB >> 17332074

Interpretation of oral fluid tests for drugs of abuse.

Edward J Cone1, Marilyn A Huestis.   

Abstract

Oral fluid testing for drugs of abuse offers significant advantages over urine as a test matrix. Collection can be performed under direct observation with reduced risk of adulteration and substitution. Drugs generally appear in oral fluid by passive diffusion from blood, but also may be deposited in the oral cavity during oral, smoked, and intranasal administration. Drug metabolites also can be detected in oral fluid. Unlike urine testing, there may be a close correspondence between drug and metabolite concentrations in oral fluid and in blood. Interpretation of oral fluid results for drugs of abuse should be an iterative process whereby one considers the test results in the context of program requirements and a broad scientific knowledge of the many factors involved in determining test outcome. This review delineates many of the chemical and metabolic processes involved in the disposition of drugs and metabolites in oral fluid that are important to the appropriate interpretation of oral fluid tests. Chemical, metabolic, kinetic, and analytic parameters are summarized for selected drugs of abuse, and general guidelines are offered for understanding the significance of oral fluid tests.

Mesh:

Substances:

Year:  2007        PMID: 17332074      PMCID: PMC2700061          DOI: 10.1196/annals.1384.037

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  184 in total

1.  On-site testing of saliva and sweat with Drugwipe and determination of concentrations of drugs of abuse in saliva, plasma and urine of suspected users.

Authors:  N Samyn; C van Haeren
Journal:  Int J Legal Med       Date:  2000       Impact factor: 2.686

2.  Passive inhalation of cocaine.

Authors:  E J Cone; D Yousefnejad; M J Hillsgrove; B Holicky; W D Darwin
Journal:  J Anal Toxicol       Date:  1995-10       Impact factor: 3.367

3.  Saliva cotinine as an indicator of cigarette smoking in adolescents.

Authors:  A D McNeill; M J Jarvis; R West; M A Russell; A Bryant
Journal:  Br J Addict       Date:  1987-12

4.  Urinary metabolites of dl-methadone in maintenance subjects.

Authors:  H R Sullivan; S L Due
Journal:  J Med Chem       Date:  1973-08       Impact factor: 7.446

5.  Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study.

Authors:  M A ElSohly; H deWit; S R Wachtel; S Feng; T P Murphy
Journal:  J Anal Toxicol       Date:  2001-10       Impact factor: 3.367

6.  Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.

Authors:  M Mas; M Farré; R de la Torre; P N Roset; J Ortuño; J Segura; J Camí
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

7.  High performance liquid chromatographic assays of the illicit designer drug "Ecstasy", a modified amphetamine, with applications to stability, partitioning and plasma protein binding.

Authors:  E R Garrett; K Seyda; P Marroum
Journal:  Acta Pharm Nord       Date:  1991

8.  The detection of acetylcodeine and 6-acetylmorphine in opiate positive urines.

Authors:  C L O'Neal; A Poklis
Journal:  Forensic Sci Int       Date:  1998-07-06       Impact factor: 2.395

9.  The validation of self-reported smoking status by analysing cotinine levels in stimulated and unstimulated saliva, serum and urine.

Authors:  V Binnie; S McHugh; L Macpherson; B Borland; K Moir; K Malik
Journal:  Oral Dis       Date:  2004-09       Impact factor: 3.511

10.  CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone.

Authors:  S V Otton; M Schadel; S W Cheung; H L Kaplan; U E Busto; E M Sellers
Journal:  Clin Pharmacol Ther       Date:  1993-11       Impact factor: 6.875

View more
  21 in total

1.  Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration.

Authors:  Garry Milman; Allan J Barnes; David M Schwope; Eugene W Schwilke; William D Darwin; Robert S Goodwin; Deanna L Kelly; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2010-06-08       Impact factor: 8.327

Review 2.  Incorporating salivary biomarkers into nursing research: an overview and review of best practices.

Authors:  Douglas A Granger; Sara B Johnson; Sarah L Szanton; Dorothée Out; Lynette Lau Schumann
Journal:  Biol Res Nurs       Date:  2012-05-15       Impact factor: 2.522

3.  Cannabinoid stability in authentic oral fluid after controlled cannabis smoking.

Authors:  Dayong Lee; Garry Milman; David M Schwope; Allan J Barnes; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2012-04-24       Impact factor: 8.327

Review 4.  Feasibility of Using Oral Fluid for Therapeutic Drug Monitoring of Antiepileptic Drugs.

Authors:  Morgan Patrick; Samuel Parmiter; Sherif Hanafy Mahmoud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-03       Impact factor: 2.441

5.  Identifying prenatal cannabis exposure and effects of concurrent tobacco exposure on neonatal growth.

Authors:  Teresa R Gray; Rina D Eiden; Kenneth E Leonard; Gerard J Connors; Shannon Shisler; Marilyn A Huestis
Journal:  Clin Chem       Date:  2010-07-13       Impact factor: 8.327

6.  Design of the NIDA clinical trials network validation study of tobacco, alcohol, prescription medications, and substance use/misuse (TAPS) tool.

Authors:  Li-Tzy Wu; Jennifer McNeely; Geetha A Subramaniam; Gaurav Sharma; Paul VanVeldhuisen; Robert P Schwartz
Journal:  Contemp Clin Trials       Date:  2016-07-19       Impact factor: 2.226

7.  Impact of oral fluid collection device on cannabinoid stability following smoked cannabis.

Authors:  Sébastien Anizan; Mateus M Bergamaschi; Allan J Barnes; Garry Milman; Nathalie Desrosiers; Dayong Lee; David A Gorelick; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2014-07-03       Impact factor: 3.345

8.  Monitoring pregnant women's illicit opiate and cocaine use with sweat testing.

Authors:  Bertrand R Brunet; Allan J Barnes; Robin E Choo; Patrick Mura; Hendre E E Jones; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2010-02       Impact factor: 3.681

9.  Prenatal tobacco exposure, biomarkers for tobacco in meconium, and neonatal growth outcomes.

Authors:  Sarah K Himes; Laura R Stroud; Karl B Scheidweiler; Raymond S Niaura; Marilyn A Huestis
Journal:  J Pediatr       Date:  2012-12-01       Impact factor: 4.406

10.  Comparison of timeline follow-back self-report and oral fluid testing to detect substance use in adult primary care patients.

Authors:  Courtney D Nordeck; Jan Gryczynski; Kevin E O'Grady; Kathryn Polak; Dace S Svikis; Jennifer McNeely; Li-Tzy Wu; Robert P Schwartz
Journal:  Drug Alcohol Depend       Date:  2020-02-22       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.